Patents Assigned to SYNTHON BIOPHARMACEUTICAL B.V.
  • Publication number: 20170080103
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Application
    Filed: May 22, 2015
    Publication date: March 23, 2017
    Applicant: SYNTHON BIOPHARMACEUTICAL B.V.
    Inventors: Gerardus Joseph Andreas ARIAANS, Rudy Gerardus Elisabeth COUMANS